United Therapeutics CEO Sells Stock Options, Securing Billions in Profit

On May 11–12, United Therapeutics Corp. (NASDAQ: UTHR) CEO Martin Rothblatt and CFO James Edgemon, pursuant to a pre-established Rule 10b5-1 trading plan, exercised their stock options and sold an equivalent number of common shares in the open market. Over the two-day period, Rothblatt exercised approximately 10,000 options and sold them in full, generating about $11 million (roughly KRW 15 billion). Edgemon carried out a similar exercise and sale of options of comparable size. Both executives continue to hold tens of thousands of shares, directly or indirectly.

In its Q1 2026 financial results announced on May 6, the company reported revenues of $781.5 million, a 2 percent year-over-year decline, and emphasized its development plan for ralinepag DPI, a clinical candidate for pulmonary arterial hypertension and pulmonary fibrosis. The company also secured FDA approval to initiate the first-in-human trial of “UHeart,” a transplantable organ candidate derived from gene-edited pig hearts, drawing attention to its efforts in alternative organ development.

United Therapeutics is a biotech specializing in rare and severe cardiopulmonary diseases, best known for its pulmonary arterial hypertension therapy Tyvaso. The company has been aggressively investing in regenerative medicine and xenotransplantation research to expand the supply of transplantable lungs and hearts. Martin Rothblatt, the firm’s founder and a public advocate for organ transplantation and life-extension technologies, has in recent years repeatedly disclosed large option vestings followed by planned equity sales.